WILLIAM JL RIEFLIN

CIK 1182471 · Executive Chairman · last filed 2025-05-19

WILLIAM JL RIEFLIN is an Executive Chairman who has filed 53 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing, for LYEL, was dated May 19, 2025. Across all open-market trades the lifetime net is +$275.2K, making them a net buyer over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

5

Total Filings

53

Lifetime Open-Market Net

$275.2K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
LYEL Director $13.50 $0 5 2025-05-19
RAPT Therapeutics, Inc. (RAPT) Delisted Director 94,722 $58.01 $5.49M $258.2K 11 2024-05-23
NGM BIOPHARMACEUTICALS INC (NGM) Delisted Executive Chairman 0 $1.54 $0 $0 6 2024-04-08
XENOPORT INC (XNPT) Delisted Director 0 $17.0K 24 2016-07-06
Anacor Pharmaceuticals, Inc. (ANAC) Delisted Director 0 $10.19 $0 $0 7 2016-06-24

Recent Filings

53 filings
Form 4 transactions across all companies, newest first.
Filed Symbol Action Net Shares Net $ Link
2025-05-19 LYEL Grant (A) $0 EDGAR
2024-06-17 LYEL Grant (A) $0 EDGAR
2024-05-23 RAPT Therapeutics, Inc. (RAPT) Delisted Grant (A) $0 EDGAR
2024-04-08 NGM BIOPHARMACEUTICALS INC (NGM) Delisted Mixed −2,774,340 $0 EDGAR
2024-04-01 RAPT Therapeutics, Inc. (RAPT) Delisted Grant (A) $0 EDGAR
2023-09-08 LYEL Grant (A) $0 EDGAR
2023-06-20 LYEL Grant (A) $0 EDGAR
2023-05-25 RAPT Therapeutics, Inc. (RAPT) Delisted Grant (A) $0 EDGAR
2023-05-12 NGM BIOPHARMACEUTICALS INC (NGM) Delisted Grant (A) $0 EDGAR
2023-04-10 RAPT Therapeutics, Inc. (RAPT) Delisted Grant (A) $0 EDGAR
Showing 110 of 53
Page 1 of 6
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.